RESUMEN
The pharmacokinetic behaviours of amoxicillin (AMX) and clavulanic acid (CA) in swine were studied after either an intravenous or oral administration of AMX (10 mg/kg) and CA (2.5 mg/kg). The concentrations of these two medicines in swine plasma were determined using high-performance liquid chromatographic-tandem mass spectrometry, and the data were analysed using a noncompartmental model with the WinNonlin software. After intravenous administration, both substances were absorbed rapidly and reached their effective therapeutic concentration quickly. CA was eliminated more slowly compared with AMX. Moreover, the distribution volume of AMX was larger than that of CA, suggesting that AMX could penetrate tissues better. After oral administration of the granular formulation, no significant difference was observed in the mean elimination half-life value between AMX and CA. The mean maximal plasma concentrations of AMX and CA, reached after 1.14 and 1.32 hr, were 2.58 and 1.91 µg/m, respectively. The mean oral bioavailability of AMX and CA was 23.6% and 26.4%, respectively. After oral administration, the T>MIC50 for three common respiratory pathogens was over 6.12 hr. Therefore, oral administration could be more effective in the clinical therapy of pigs, especially when administered twice daily.
Asunto(s)
Combinación Amoxicilina-Clavulanato de Potasio/farmacocinética , Antibacterianos/farmacocinética , Porcinos/sangre , Administración Oral , Combinación Amoxicilina-Clavulanato de Potasio/administración & dosificación , Combinación Amoxicilina-Clavulanato de Potasio/sangre , Animales , Antibacterianos/administración & dosificación , Antibacterianos/sangre , Área Bajo la Curva , Disponibilidad Biológica , Femenino , Semivida , Inyecciones Intravenosas/veterinaria , MasculinoRESUMEN
This study examined the pharmacokinetics of orally administered amoxicillin and clavulanic acid tablets (Clavamox, 125 mg/kg PO q12h for 9 doses) in domestic hens and examined both amoxicillin and clavulanic acid concentrations in eggs. Therapeutic plasma concentrations (0.5 µg/mL) of amoxicillin were not reached at any time point, and no amoxicillin was detected in plasma after 2 hours. Pharmacokinetic parameters could not be calculated. The clavulanic acid half-life was 1.1 hours and it was detected up to 8 hours after dosing. No amoxicillin was detected in eggs 4 days postdosing, nor was clavulanic acid detected in any eggs during the same time period. On the basis of these results, orally dosing hens with amoxicillin and clavulanic acid tablets at 125 mg/kg PO q12h does not reach therapeutic plasma concentrations. Additional studies are needed to examine different doses and formulations of medication to determine better dosing and withdrawal recommendations for domestic chickens.
Asunto(s)
Combinación Amoxicilina-Clavulanato de Potasio/farmacocinética , Antibacterianos/farmacocinética , Pollos/metabolismo , Óvulo/química , Administración Oral , Combinación Amoxicilina-Clavulanato de Potasio/química , Animales , Antibacterianos/química , Residuos de Medicamentos , FemeninoRESUMEN
BACKGROUND: Amoxicillin has been in use since the 1970s; it is the most widely used penicillin both alone and in combination with the ß-lactamase clavulanic acid. OBJECTIVES: In this narrative review, we re-examine the properties of oral amoxicillin and clavulanic acid and provide guidance on their use, with emphasis on the preferred use of amoxicillin alone. SOURCES: Published medical literature (MEDLINE database via Pubmed). CONTENT: While amoxicillin and clavulanic acid have similar half-lives, clavulanic acid is more protein bound and even less heat stable than amoxicillin, with primarily hepatic metabolism. It is also more strongly associated with gastrointestinal side effects, including Clostridium difficile infection, and, thus, in oral combination formulations, limits the maximum daily dose of amoxicillin that can be given. The first ratio for an amoxicillin-clavulanic acid combination was set at 4:1 due to clavulanic acid's high affinity for ß-lactamases; ratios of 2:1, 7:1, 14:1 and 16:1 are currently available in various regions. Comparative effectiveness data for the different ratios are scarce. Amoxicillin-clavulanic acid is often used as empiric therapy for many of the World Health Organization's Priority Infectious Syndromes in adults and children, leading to extensive consumption, when some of these syndromes could be handled with a delayed antibiotic prescription approach or amoxicillin alone. IMPLICATIONS: Using available epidemiological and pharmacokinetic data, we provide guidance on indications for amoxicillin versus amoxicillin-clavulanic acid and on optimal oral administration, including choice of combination ratio. More data are needed, particularly on heat stability, pharmacodynamic effects and emergence of resistance in 'real-world' clinical settings.
Asunto(s)
Combinación Amoxicilina-Clavulanato de Potasio/administración & dosificación , Amoxicilina/administración & dosificación , Administración Oral , Amoxicilina/farmacocinética , Combinación Amoxicilina-Clavulanato de Potasio/farmacocinética , Cálculo de Dosificación de Drogas , Estabilidad de Medicamentos , Humanos , Guías de Práctica Clínica como AsuntoRESUMEN
INTRODUCTION: High morbidity and mortality rates of proven bacterial infection are the main reason for substantial use of intravenous antibiotics in neonates during the first week of life. In older children, intravenous-to-oral switch after 48 hours of intravenous therapy has been shown to have many advantages and is nowadays commonly practised. We, therefore, aim to evaluate the effectiveness, safety and cost-effectiveness of an early intravenous-to-oral switch in neonates with a probable bacterial infection. METHODS AND ANALYSIS: We present a protocol for a multicentre randomised controlled trial assessing the non-inferiority of an early intravenous-to-oral antibiotic switch compared with a full course of intravenous antibiotics in neonates (0-28 days of age) with a probable bacterial infection. Five hundred and fifty patients will be recruited in 17 hospitals in the Netherlands. After 48 hours of intravenous treatment, they will be assigned to either continue with intravenous therapy for another 5 days (control) or switch to amoxicillin/clavulanic acid suspension (intervention). Both groups will be treated for a total of 7 days. The primary outcome will be bacterial (re)infection within 28 days after treatment completion. Secondary outcomes are the pharmacokinetic profile of oral amoxicillin/clavulanic acid, the impact on quality of life, cost-effectiveness, impact on microbiome development and additional yield of molecular techniques in diagnosis of probable bacterial infection. ETHICS AND DISSEMINATION: This study has been approved by the Medical Ethics Committee of the Erasmus Medical Centre. Results will be presented in peer-reviewed journals and at international conferences. TRIAL REGISTRATION NUMBER: NCT03247920.
Asunto(s)
Combinación Amoxicilina-Clavulanato de Potasio/administración & dosificación , Antibacterianos/administración & dosificación , Infecciones Bacterianas/tratamiento farmacológico , Administración Intravenosa , Administración Oral , Combinación Amoxicilina-Clavulanato de Potasio/economía , Combinación Amoxicilina-Clavulanato de Potasio/farmacocinética , Combinación Amoxicilina-Clavulanato de Potasio/uso terapéutico , Antibacterianos/economía , Antibacterianos/farmacocinética , Antibacterianos/uso terapéutico , Infecciones Bacterianas/diagnóstico , Infecciones Bacterianas/economía , Infecciones Bacterianas/microbiología , Protocolos Clínicos , Análisis Costo-Beneficio , Estudios de Seguimiento , Microbioma Gastrointestinal , Humanos , Recién Nacido , Países Bajos , Seguridad del Paciente , Método Simple Ciego , Resultado del TratamientoRESUMEN
The pharmacokinetic properties of amoxicillin (AMX) and clavulanic acid (CLV) were studied in healthy cats following single intravenous and oral dosage of 10 mg/kg of AMX and 2.5 mg/kg of CLV. The drug concentrations in plasma were determined by a high-performance liquid chromatographic-tandem mass spectrometry (LC-MS-MS) method validated for canine plasma and further subjected to noncompartmental analysis. After intravenous injection, no significant difference (p > 0.05) was found in the volume of distribution of these two compounds. In addition, AMX and CLV were both rapidly eliminated from plasma with a clearance of 0.453 and 0.921 L hr-1 kg-1 , respectively; however, a quicker elimination was observed for CLV (p < 0.01). After oral administration, both drugs were characterized by rapid absorption with an absorption half-life of 1.10 and 0.70 hr for AMX and CLV, respectively. Significant differences were observed between their absorption rates (p < 0.05). However, the oral bioavailabilities of AMX and CLV (75.57% and 98.15%, respectively) were not statistically different (p > 0.05). A total intravenous or oral dose at 12.5 mg/kg of AMX and CLV (4:1) is predicted to be effective for treating those bacterial species isolated from cats with a minimum inhibitory concentration (MIC) of ≤0.25 µg/ml for 12 hr, based on a time above the MIC (T > MIC) of 40%.
Asunto(s)
Combinación Amoxicilina-Clavulanato de Potasio/farmacocinética , Antibacterianos/farmacocinética , Gatos/sangre , Administración Oral , Combinación Amoxicilina-Clavulanato de Potasio/administración & dosificación , Combinación Amoxicilina-Clavulanato de Potasio/sangre , Animales , Antibacterianos/administración & dosificación , Antibacterianos/sangre , Área Bajo la Curva , Estudios Cruzados , Femenino , Semivida , Inyecciones Intravenosas , MasculinoRESUMEN
Objetivo: Evaluar mediante análisis farmacocinético/farmadocinámico (PK/PD) si el cambio en la sensibilidad antimicrobiana tras la introducción en España de la vacuna anti-neumocócica heptavalente (VNC7) ha implicado cambios en la adecuación del tratamiento antibiótico de la otitis media aguda (OMA) en niños. Materiales y métodos: Los parámetros PK y datos de sensibilidad de Streptococcus pneumoniae y Haemophilus influenzae fueron obtenidos de la bibliografía. Mediante simulación de Montecarlo, calculamos la probabilidad de éxito del tratamiento antibiótico, expresada como fracción de respuesta acumulada (CFR). Para amoxicilina y amoxicilina/ácido clavulánico, el objetivo farmacodinámico considerado fue el tiempo durante el cual las concentraciones libres en sangre permanecen por encima de la concentración mínima inhibitoria (CMI), expresado como porcentaje del intervalo de dosificación (fT>CMI≥50%). Para cefuroxima axetilo y cefotaxima, el objetivo fue fT>CMI≥60%. Valores de CFR≥90% se consideraron indicativos de éxito. Resultados: Si se tienen en cuenta todos los serotipos de S. pneumoniae, amoxicilina y cefotaxima proporcionaron una alta probabilidad de éxito, sin apenas diferencia entre ambos periodos. En el caso de H. influenzae, los valores de CFR fueron más altos con amoxicilina/ácido clavulánico que con amoxicilina. Para ambos microorganismos, las probabilidades de éxito de cefuroxima axetilo fueron bajas en ambos periodos de estudio. Conclusiones: La introducción de la vacuna PCV7 no ha implicado cambios en la probabilidad de éxito del tratamiento antibiótico empírico de la OMA. Hemos demostrado la utilidad del análisis PK/PD para detectar cambios en la adecuación del tratamiento antibiótico tras la implantación de una vacuna, proporcionando información complementaria al seguimiento de los valores de CMI
Objetivo: Evaluar mediante análisis farmacocinético/farmadocinámico (PK/PD) si el cambio en la sensibilidad antimicrobiana tras la introducción en España de la vacuna anti-neumocócica heptavalente (VNC7) ha implicado cambios en la adecuación del tratamiento antibiótico de la otitis media aguda (OMA) en niños. Materiales y métodos: Los parámetros PK y datos de sensibilidad de Streptococcus pneumoniae y Haemophilus influenzae fueron obtenidos de la bibliografía. Mediante simulación de Montecarlo, calculamos la probabilidad de éxito del tratamiento antibiótico, expresada como fracción de respuesta acumulada (CFR). Para amoxicilina y amoxicilina/ácido clavulánico, el objetivo farmacodinámico considerado fue el tiempo durante el cual las concentraciones libres en sangre permanecen por encima de la concentración mínima inhibitoria (CMI), expresado como porcentaje del intervalo de dosificación (fT>CMI≥50%). Para cefuroxima axetilo y cefotaxima, el objetivo fue fT>CMI≥60%. Valores de CFR≥90% se consideraron indicativos de éxito. Resultados: Si se tienen en cuenta todos los serotipos de S. pneumoniae, amoxicilina y cefotaxima proporcionaron una alta probabilidad de éxito, sin apenas diferencia entre ambos periodos. En el caso de H. influenzae, los valores de CFR fueron más altos con amoxicilina/ácido clavulánico que con amoxicilina. Para ambos microorganismos, las probabilidades de éxito de cefuroxima axetilo fueron bajas en ambos periodos de estudio. Conclusiones: La introducción de la vacuna PCV7 no ha implicado cambios en la probabilidad de éxito del tratamiento antibiótico empírico de la OMA. Hemos demostrado la utilidad del análisis PK/PD para detectar cambios en la adecuación del tratamiento antibiótico tras la implantación de una vacuna, proporcionando información complementaria al seguimiento de los valores de CMI
Asunto(s)
Humanos , Niño , Otitis Media/tratamiento farmacológico , Antibacterianos/farmacocinética , Vacunas Neumococicas/administración & dosificación , Vacuna Neumocócica Conjugada Heptavalente/administración & dosificación , Enfermedad Aguda/terapia , Otitis Media/epidemiología , España/epidemiología , Combinación Amoxicilina-Clavulanato de Potasio/farmacocinética , Amoxicilina/farmacocinéticaRESUMEN
OBJECTIVE: To evaluate, by applying pharmacokinetic/pharmacodynamic (PK/PD) analysis, if the change in antibiotic susceptibility after the introduction of the 7-valent pneumococcal conjugate vaccine (PCV7) in Spain had any influence on the usefulness of the antimicrobials more frequently used as empirical treatment of pediatric acute otitis media (AOM). METHODS: PK parameters and susceptibility of Streptococcus pneumoniae and Haemophilus influenzae were obtained from bibliography. Monte Carlo simulation was used to estimate the cumulative fraction of response (CFR), understood as the expected probability of therapy success. For amoxicillin and amoxicillin/clavulanate, the target was free antibiotic concentration remaining above the minimum inhibitory concentration (MIC) for ≥50% of the dosing interval (fT>MIC≥50%), whereas for cefuroxime axetil and cefotaxime, the target was fT>MIC≥60%. CFR values ≥90% were considered successful. RESULTS: When all serotypes of S. pneumoniae are considered, amoxicillin and cefotaxime turned out to reach a high probability of success, and difference before and after vaccination was scarce. For H. influenzae, CFR values were higher with amoxicillin/clavulanate than with amoxicillin. For both microorganisms, cefuroxime axetil resulted in low probability of success in the two periods of study. CONCLUSIONS: We have shown that the introduction of the PCV7 vaccination did not lead to changes in the probability of success of the current empiric treatments of the AOM. Integrated PK/PD analysis has demonstrated to be a useful tool to identify changes in antimicrobial activity after the implantation of a vaccination program, providing complementary information to the simple assessment of MIC values.
Asunto(s)
Antibacterianos/farmacocinética , Antibacterianos/uso terapéutico , Vacuna Neumocócica Conjugada Heptavalente/uso terapéutico , Otitis Media/tratamiento farmacológico , Otitis Media/prevención & control , Vacunas Estreptocócicas/uso terapéutico , Algoritmos , Amoxicilina/farmacocinética , Amoxicilina/uso terapéutico , Combinación Amoxicilina-Clavulanato de Potasio/farmacocinética , Combinación Amoxicilina-Clavulanato de Potasio/uso terapéutico , Cefuroxima/análogos & derivados , Cefuroxima/farmacocinética , Cefuroxima/uso terapéutico , Niño , Femenino , Haemophilus influenzae/efectos de los fármacos , Humanos , Masculino , Pruebas de Sensibilidad Microbiana , Método de Montecarlo , Otitis Media/microbiología , España , Streptococcus pneumoniae/efectos de los fármacos , Resultado del Tratamiento , VacunaciónRESUMEN
AIMS: Beta-lactam dose optimization in critical care is a current priority. We aimed to review the pharmacokinetics (PK) of three commonly used beta-lactams (amoxicillin ± clavulanate, piperacillin-tazobactam and meropenem) to compare PK parameters reported in critically and noncritically ill neonates, children and adults, and to investigate whether allometric and maturation scaling principles could be applied to describe changes in PK parameters through life. METHODS: A systematic review of PK studies of the three drugs was undertaken using MEDLINE and EMBASE. PK parameters and summary statistics were extracted and scaled using allometric principles to 70 kg individual for comparison. Pooled data were used to model clearance maturation and decline using a sigmoidal (Hill) function. RESULTS: A total of 130 papers were identified. Age ranged from 29 weeks to 82 years and weight from 0.9-200 kg. PK parameters from critically ill populations were reported with wider confidence intervals than those in healthy volunteers, indicating greater PK variability in critical illness. The standard allometric size and sigmoidal maturation model adequately described increasing clearance in neonates, and a sigmoidal model was also used to describe decline in older age. Adult weight-adjusted clearance was achieved at approximately 2 years postmenstrual age. Changes in volume of distribution were well described by the standard allometric model, although amoxicillin data suggested a relatively higher volume of distribution in neonates. CONCLUSIONS: Critical illness is associated with greater PK variability than in healthy volunteers. The maturation models presented will be useful for optimizing beta-lactam dosing, although a prospective, age-inclusive study is warranted for external validation.
Asunto(s)
Antibacterianos/farmacocinética , Infecciones Bacterianas/tratamiento farmacológico , Enfermedad Crítica/terapia , Inhibidores de beta-Lactamasas/farmacocinética , Adulto , Factores de Edad , Combinación Amoxicilina-Clavulanato de Potasio/administración & dosificación , Combinación Amoxicilina-Clavulanato de Potasio/farmacocinética , Antibacterianos/administración & dosificación , Variación Biológica Poblacional , Niño , Relación Dosis-Respuesta a Droga , Voluntarios Sanos , Humanos , Recién Nacido , Meropenem/administración & dosificación , Meropenem/farmacocinética , Pruebas de Sensibilidad Microbiana , Combinación Piperacilina y Tazobactam/administración & dosificación , Combinación Piperacilina y Tazobactam/farmacocinética , Inhibidores de beta-Lactamasas/administración & dosificaciónRESUMEN
The use of human generic amoxicillin-clavulanic acid formulations in veterinary medicine is currently lacking supportive evidence. This pilot study was conducted to determine preliminary pharmacokinetic parameters and relative oral bioavailability of a human generic and veterinary proprietary 4:1 amoxicillin-clavulanic acid formulation in healthy dogs to evaluate whether drug exposure was similar and to determine if further comparative investigation is warranted. Each dog received a single oral dose of each formulation containing 500:125 mg of amoxicillin-clavulanic acid at two separate instances with a 2 wk washout period between product administration. Following drug administration, blood was collected at fixed times over 24 hr to measure plasma amoxicillin and clavulanic acid concentrations using liquid chromatography-mass spectrometry. There were no statistically significant differences between pharmacokinetic parameters of either formulation. Clavulanic acid showed greater between-dog variation in drug exposure between formulations compared with amoxicillin and was also observed to be more variable within the veterinary proprietary formulation. The average relative oral bioavailability was 98.2% (23.6% coefficient of variation) for amoxicillin and 152.6% (64.3% coefficient of variation) for clavulanic acid between formulations. This pilot investigation supports the need for further bioequivalence studies regarding these formulations before commenting on product interchangeability.
Asunto(s)
Combinación Amoxicilina-Clavulanato de Potasio , Antibacterianos , Perros , Inhibidores de beta-Lactamasas , Animales , Perros/sangre , Perros/metabolismo , Femenino , Masculino , Administración Oral , Combinación Amoxicilina-Clavulanato de Potasio/administración & dosificación , Combinación Amoxicilina-Clavulanato de Potasio/sangre , Combinación Amoxicilina-Clavulanato de Potasio/farmacocinética , Antibacterianos/administración & dosificación , Antibacterianos/sangre , Antibacterianos/farmacocinética , Área Bajo la Curva , Inhibidores de beta-Lactamasas/administración & dosificación , Inhibidores de beta-Lactamasas/sangre , Inhibidores de beta-Lactamasas/farmacocinética , Disponibilidad Biológica , Estudios Cruzados , Composición de Medicamentos , Medicamentos Genéricos , Semivida , Proyectos Piloto , Distribución AleatoriaRESUMEN
Objectives: To determine antibiotic susceptibility in isolates of Streptococcus pneumoniae and Haemophilus influenzae collected in 2014-16 from Russia. Methods: MICs were determined by CLSI broth microdilution and susceptibility was assessed using CLSI, EUCAST and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints. Results: A total of 279 S. pneumoniae and 279 H. influenzae were collected. Overall, 67.0% of S. pneumoniae were penicillin susceptible by CLSI oral/EUCAST and 93.2% by CLSI intravenous (iv) breakpoints. All were fluoroquinolone susceptible, with amoxicillin, amoxicillin/clavulanic acid and ceftriaxone susceptibility ≥92.8% by CLSI and PK/PD breakpoints. Isolates showed lower susceptibility to cefuroxime, cefaclor, macrolides and trimethoprim/sulfamethoxazole by CLSI criteria: 85.0%, 76.7%, 68.8% and 67.7%, respectively. Generally, susceptibility was slightly lower by EUCAST criteria, except for cefaclor, for which the difference in susceptibility was much greater. Penicillin-resistant isolates had low susceptibility (≤60%) to all agents except fluoroquinolones. All 279 H. influenzae were ceftriaxone susceptible, 15.4% were ß-lactamase positive and ≥97.5% were amoxicillin/clavulanic acid susceptible (CLSI, EUCAST and PK/PD breakpoints). Four isolates were fluoroquinolone non-susceptible by current EUCAST criteria. A major discrepancy was found with azithromycin susceptibility between CLSI (99.3%) and EUCAST and PK/PD (2.2%) breakpoints. Trimethoprim/sulfamethoxazole was poorly active (62.7% susceptible). Conclusions: Susceptibility to penicillin (oral), macrolides and trimethoprim/sulfamethoxazole was low in S. pneumoniae from Russia. However, isolates were fully susceptible to fluoroquinolones and ≥92.8% were susceptible to amoxicillin, amoxicillin/clavulanic acid and ceftriaxone. Isolates of H. influenzae only showed reduced susceptibility to ampicillin, cefaclor, clarithromycin and trimethoprim/sulfamethoxazole. Some differences were detected between CLSI, EUCAST and PK/PD breakpoints, especially with cefaclor, cefuroxime and macrolides. These data suggest further efforts are required to harmonize international breakpoints.
Asunto(s)
Antibacterianos/farmacología , Farmacorresistencia Bacteriana Múltiple , Monitoreo Epidemiológico , Haemophilus influenzae/efectos de los fármacos , Streptococcus pneumoniae/efectos de los fármacos , Adolescente , Adulto , Anciano , Amoxicilina/farmacocinética , Amoxicilina/farmacología , Combinación Amoxicilina-Clavulanato de Potasio/farmacocinética , Combinación Amoxicilina-Clavulanato de Potasio/farmacología , Antibacterianos/farmacocinética , Niño , Infecciones Comunitarias Adquiridas/epidemiología , Infecciones Comunitarias Adquiridas/microbiología , Infecciones por Haemophilus/epidemiología , Humanos , Macrólidos/farmacocinética , Macrólidos/farmacología , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad , Infecciones Neumocócicas/epidemiología , Infecciones del Sistema Respiratorio/epidemiología , Infecciones del Sistema Respiratorio/microbiología , Federación de Rusia/epidemiología , Encuestas y Cuestionarios , Adulto JovenRESUMEN
Objectives: To determine antimicrobial susceptibility in isolates of Streptococcus pneumoniae and Haemophilus influenzae collected in 2014-16 from patients with community-acquired respiratory tract infections in Greece. Methods: MICs were determined by CLSI broth microdilution and susceptibility assessed using CLSI, EUCAST and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints. Results: A total of 99 S. pneumoniae and 52 H. influenzae isolates were collected. Overall, 36.4% of S. pneumoniae were penicillin susceptible by CLSI oral/EUCAST and 88.9% by CLSI intravenous (iv) breakpoints. All were fluoroquinolone susceptible with ≥94% of isolates also susceptible to amoxicillin, amoxicillin/clavulanic acid and ceftriaxone by CLSI and PK/PD breakpoints. Trimethoprim/sulfamethoxazole, cefuroxime, cefaclor and macrolides were less active, with rates of susceptibility of 83.8%, 69.7%, 50.5% and 49.5%, respectively, by CLSI. Generally susceptibility was the same or slightly lower by EUCAST, but the cefaclor difference was much greater. Among H. influenzae, 15.4% of isolates were ß-lactamase positive. Susceptibility to amoxicillin/clavulanic acid, ceftriaxone, cefuroxime and the fluoroquinolones was seen in >95% of isolates by CLSI criteria. Susceptibility to azithromycin was seen in 94.2% of isolates using CLSI breakpoints, but clarithromycin susceptibility was lower (61.5%). However, susceptibility to both macrolides was seen in <5% of isolates by PK/PD and EUCAST criteria. Susceptibility to trimethoprim/sulfamethoxazole was seen in 71.2% of isolates. Conclusions: Owing to the high prevalence of macrolide resistance among S. pneumoniae and the reduced activity of clarithromycin against H. influenzae, it appears that these agents are not appropriate as monotherapy for community-acquired pneumonia in Greece. Amoxicillin/clavulanic acid, on the other hand, maintained excellent in vitro activity and, as opposed to the similarly effective fluoroquinolones, is safe to use in paediatric patients.
Asunto(s)
Antibacterianos/farmacología , Farmacorresistencia Bacteriana Múltiple , Monitoreo Epidemiológico , Haemophilus influenzae/efectos de los fármacos , Streptococcus pneumoniae/efectos de los fármacos , Adolescente , Adulto , Anciano , Combinación Amoxicilina-Clavulanato de Potasio/farmacocinética , Combinación Amoxicilina-Clavulanato de Potasio/farmacología , Antibacterianos/farmacocinética , Niño , Infecciones Comunitarias Adquiridas/epidemiología , Fluoroquinolonas/farmacocinética , Fluoroquinolonas/farmacología , Grecia/epidemiología , Infecciones por Haemophilus/epidemiología , Humanos , Macrólidos/farmacocinética , Macrólidos/farmacología , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad , Infecciones Neumocócicas/epidemiología , Infecciones del Sistema Respiratorio/epidemiología , Encuestas y Cuestionarios , Adulto JovenRESUMEN
Objectives: To determine antibiotic susceptibility in isolates of Streptococcus pneumoniae and Haemophilus influenzae collected in 2014-16 from Ukraine and the Slovak Republic. Methods: MICs were determined by CLSI broth microdilution and susceptibility was assessed using CLSI, EUCAST and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints. Results: S. pneumoniae isolates collected in Ukraine (n = 100) showed susceptibility rates ≥97% for amoxicillin, amoxicillin/clavulanic acid, penicillin [intravenous (iv) non-meningitis] and fluoroquinolones, between 83% and 86% for oral penicillin, macrolides and cefaclor, and 75% for trimethoprim/sulfamethoxazole. Susceptibility was substantially lower in the Slovak Republic (n = 95). All isolates were susceptible to the fluoroquinolones, but susceptibility to penicillin, amoxicillin, amoxicillin/clavulanic acid, cefuroxime and trimethoprim/sulfamethoxazole varied between 61% and 64%, with only 44% of isolates susceptible to the macrolides. Susceptibility of H. influenzae was more homogeneous, with susceptibility to amoxicillin/clavulanic acid, ceftriaxone, cefuroxime, azithromycin and the fluoroquinolones seen in >90% of isolates by CLSI criteria in both countries. Much greater variability was seen across breakpoints, especially for azithromycin, cefaclor and cefuroxime. The ß-lactamase rate was 5.1% (5/98) in the Slovak Republic and 7.3% (7/96) in Ukraine, but the Slovak Republic also had a relatively high rate of ß-lactamase-negative-ampicillin-resistant (BLNAR) isolates (7.1%; 7/98). Conclusions: The variability found across these two neighbouring countries illustrates the need to monitor and publish national and local resistance patterns. This information is not only critical for effective empirical therapy but can also be used to help shape and support antimicrobial stewardship efforts in order to limit antibiotic resistance.
Asunto(s)
Antibacterianos/farmacología , Farmacorresistencia Bacteriana Múltiple , Monitoreo Epidemiológico , Haemophilus influenzae/efectos de los fármacos , Streptococcus pneumoniae/efectos de los fármacos , Adolescente , Adulto , Anciano , Amoxicilina/farmacocinética , Amoxicilina/farmacología , Combinación Amoxicilina-Clavulanato de Potasio/farmacocinética , Combinación Amoxicilina-Clavulanato de Potasio/farmacología , Antibacterianos/farmacocinética , Niño , Infecciones Comunitarias Adquiridas/epidemiología , Humanos , Macrólidos/farmacocinética , Macrólidos/farmacología , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad , Infecciones del Sistema Respiratorio/epidemiología , Eslovaquia/epidemiología , Encuestas y Cuestionarios , Ucrania/epidemiología , Adulto JovenRESUMEN
OBJECTIVES: Bioequivalence (BE) criteria for amoxicillin-clavulanic acid (Co-amoxiclav) oral formulations are based on 90% confidence interval for both amoxicillin and clavulanic acid. The aim of this work is to explore the relevance of demonstrating BE of clavulanic acid in Co-amoxiclav oral formulations and also to assess the impact on safety and efficacy of product due to bioinequivalent clavulanic acid. METHODS AND KEY FINDINGS: The subtherapeutic levels of clavulanic acid would continue to exert their action against ß-lactamases due to postß-lactamase inhibitor effect. Additionally, only minute quantities are required to inhibit ß-lactamases. Majority of adverse effects associated with Co-amoxiclav are of less serious nature, therefore, risk due to suprabioavailable clavulanic acid was determined to be low. 'Very rapid clavulanic acid release' in in vitro dissolution test would ensure that clinically significant differences between test and reference formulations if any are detected in advance. As an additional risk mitigation strategy, WHO recommends qualitative and quantitative composition similarity between test and reference formulations to ensure excipients do not adversely impact bioavailability. CONCLUSIONS: Co-amoxiclav with non-bioequivalent clavulanic acid, but bioequivalent amoxicillin would still achieve its therapeutic objectives without exposing patients to unwanted adverse effects. Therefore, the current regulatory criterion of demonstrating BE of clavulanic acid appears conservative.
Asunto(s)
Combinación Amoxicilina-Clavulanato de Potasio/administración & dosificación , Combinación Amoxicilina-Clavulanato de Potasio/farmacocinética , Antibacterianos/administración & dosificación , Antibacterianos/farmacocinética , Ácido Clavulánico/farmacocinética , Administración Oral , Combinación Amoxicilina-Clavulanato de Potasio/efectos adversos , Antibacterianos/efectos adversos , Ácido Clavulánico/administración & dosificación , Ácido Clavulánico/efectos adversos , Humanos , Pruebas de Sensibilidad Microbiana , Equivalencia Terapéutica , Inhibidores de beta-Lactamasas/administración & dosificación , Inhibidores de beta-Lactamasas/efectos adversos , Inhibidores de beta-Lactamasas/farmacocinéticaRESUMEN
Drug-induced liver injury includes a spectrum of pathologies, some related to the mode of injury, some to the cell type primarily damaged. Among these, drug-induced bile duct injury is characterized by the destruction of the biliary epithelium following exposure to a drug. Most of the drugs associated with bile duct injury cause immune-mediated lesions to the epithelium of interlobular ducts. These share common histopathological features with primary biliary cholangitis, such as inflammation and necrosis at the expense of cholangiocytes and, if the insult persists, bile duct loss and biliary cirrhosis. Some drugs selectively target larger ducts. Such injury is often dose-dependent and thought to be the result of intrinsic drug toxicity. The histological changes resemble those seen in primary sclerosing cholangitis. This overview focuses on the clinical and pathological features of bile duct injury associated with drug treatment and on the immunological and biochemical effects that drugs exert on the biliary epithelium. This article is part of a Special Issue entitled: Cholangiocytes in Health and Disease edited by Jesus Banales, Marco Marzioni, Nicholas LaRusso and Peter Jansen.
Asunto(s)
Conductos Biliares/patología , Enfermedad Hepática Inducida por Sustancias y Drogas/patología , Colangitis Esclerosante/inducido químicamente , Colestasis/inducido químicamente , Células Epiteliales/efectos de los fármacos , Combinación Amoxicilina-Clavulanato de Potasio/farmacocinética , Combinación Amoxicilina-Clavulanato de Potasio/toxicidad , Ácidos y Sales Biliares/toxicidad , Conductos Biliares/citología , Conductos Biliares/efectos de los fármacos , Conductos Biliares/metabolismo , Biomarcadores/análisis , Biotransformación , Carbamazepina/farmacocinética , Carbamazepina/toxicidad , Enfermedad Hepática Inducida por Sustancias y Drogas/tratamiento farmacológico , Enfermedad Hepática Inducida por Sustancias y Drogas/etiología , Colagogos y Coleréticos/uso terapéutico , Colangitis Esclerosante/diagnóstico , Colangitis Esclerosante/tratamiento farmacológico , Colangitis Esclerosante/patología , Colestasis/diagnóstico , Colestasis/tratamiento farmacológico , Colestasis/patología , Células Epiteliales/metabolismo , Células Epiteliales/patología , Humanos , Hígado/efectos de los fármacos , Hígado/metabolismo , Hígado/patologíaRESUMEN
Objectives: To calculate the clavulanic acid exposure of oral amoxicillin/clavulanic acid dosing regimens, to investigate variability using a population pharmacokinetic model and to explore target attainment using Monte Carlo simulations. Methods: Two groups of healthy male volunteers received amoxicillin/clavulanic acid tablets at the start of a standard meal on two separate days 1 week apart. One group (n = 14) received 875/125 mg q12h and 500/125 mg q8h and the other group (n = 15) received 500/125 mg q12h and 250/125 mg q8h. In total, 1479 blood samples were collected until 8-12 h after administration. Concentrations were analysed using non-compartmental (WinNonLin) and population pharmacokinetic (NONMEM) methods. Results: Median Cmax and AUC0-8 were 2.21 mg/L (0.21-4.35) and 4.99 mg·h/L (0.44-8.31), respectively. In 40/58 daily concentration-time profiles, Cmax and AUC0-8 of the morning dose were higher than with later doses. The final population model included a lag time (0.447 h), first-order absorption (3.99 h-1 at 8:00 h, between-subject variability 52.8%, between-occasion variability 48.5%), one distribution compartment (33.0 L, between-subject variability 23.9%) and first-order elimination (24.6 L/h, between-subject variability 26.7%). Bioavailability (fixed at 1 at 8:00 h, between-occasion variability 28.2%) and absorption rate decreased over the day. For 97.5% of the simulated population after 125 mg q12h or q8h, %fT > Ct at 0.5 mg/L was 8.33% (q12h) and 15.2% (q8h), %fT > Ct at 1 mg/L was 0% (q12h + q8h), and fAUC0-24 was 3.61 (q12h) and 5.56 (q8h) mg·h/L. Conclusions: Clavulanic acid absorption in healthy volunteers is highly variable. Bioavailability and absorption rate decrease over the day. The model developed here may serve to suggest clavulanic acid dosing regimens to optimize efficacy and prevent underdosing.
Asunto(s)
Combinación Amoxicilina-Clavulanato de Potasio/administración & dosificación , Combinación Amoxicilina-Clavulanato de Potasio/farmacocinética , Inhibidores de beta-Lactamasas/administración & dosificación , Inhibidores de beta-Lactamasas/farmacocinética , Adolescente , Adulto , Antibacterianos/administración & dosificación , Antibacterianos/farmacocinética , Disponibilidad Biológica , Análisis Químico de la Sangre , Estudios Cruzados , Voluntarios Sanos , Humanos , Masculino , Persona de Mediana Edad , Método de Montecarlo , Adulto JovenRESUMEN
This script gives a pragmatic advice for general dentists on accurate use of amoxicillin with clavulanic acid considering current literature at acute inflammatory disease. In absence of contraindications a twice daily formulation of 1g amoxicillin with clavulanic acid is the first choice for concomitant therapy after treating the cause of inflammation or prophylaxis. Compared to clindamycin the concentration of amoxicillin in teeth and bone (Hallig 2014) is higher and has less gastrointestinal side-effects (Bax 2007). Furthermore it is prescribable during pregnancy and lactation. With these advantages amoxicillin with clavulanic acid is the first choice of antibiotics in general dental medicine.
Asunto(s)
Combinación Amoxicilina-Clavulanato de Potasio/uso terapéutico , Infecciones Bacterianas/tratamiento farmacológico , Enfermedades de la Boca/tratamiento farmacológico , Combinación Amoxicilina-Clavulanato de Potasio/efectos adversos , Combinación Amoxicilina-Clavulanato de Potasio/farmacocinética , Profilaxis Antibiótica , Clindamicina/efectos adversos , Clindamicina/uso terapéutico , Relación Dosis-Respuesta a Droga , Femenino , Adhesión a Directriz , Humanos , Infecciones Oportunistas/tratamiento farmacológico , Embarazo , InvestigaciónRESUMEN
Clearance of small molecules such as amoxicillin and clavulanic acid is expected to increase during high-flux haemodialysis, which may result in lower concentrations and thus reduced efficacy. To date, clearance of amoxicillin/clavulanic acid (AMC) during high-flux haemodialysis remains largely unexplored. Using published pharmacokinetic parameters, a two-compartment model with first-order input was simulated to investigate the impact of high-flux haemodialysis on the probability of target attainment (PTA) of orally administered AMC combination therapy. The following pharmacokinetic/pharmacodynamic targets were used to calculate the PTA. For amoxicillin, the time that the free concentration remains above the minimum inhibitory concentration (MIC) of ≥50% of the dosing period (≥50%ƒT>MIC) was used. For clavulanic acid, the time that the free concentration was >0.1 mg/L of ≥45% of the dosing period (≥45%ƒT>0.1 mg/L) was used. Dialysis clearance reported in low-flux haemodialysis for both compounds was doubled to represent the likely clearance during high-flux haemodialysis. Monte Carlo simulations were performed to produce concentration-time profiles over 10 days in 1000 virtual patients. Seven different regimens commonly seen in clinical practice were explored. When AMC was dosed twice daily, the PTA was mostly ≥90% for both compounds regardless of when haemodialysis commenced. When administered once daily, the PTA was 20-30% for clavulanic acid and ≥90% for amoxicillin. The simulations suggest that once-daily orally administered AMC in patients receiving high-flux haemodialysis may result in insufficient concentrations of clavulanic acid to effectively treat infections, especially on days when haemodialysis occurs.
Asunto(s)
Combinación Amoxicilina-Clavulanato de Potasio/administración & dosificación , Combinación Amoxicilina-Clavulanato de Potasio/farmacocinética , Antibacterianos/administración & dosificación , Antibacterianos/farmacocinética , Diálisis Renal/métodos , Inhibidores de beta-Lactamasas/administración & dosificación , Inhibidores de beta-Lactamasas/farmacocinética , Quimioterapia Combinada/métodos , Humanos , Pruebas de Sensibilidad Microbiana , Método de Montecarlo , Plasma/química , Factores de TiempoRESUMEN
BACKGROUND: Prophylactic use of amoxicillin and amoxicillin/clavulanic acid, although controversial, is common in routine clinical practice in third molar surgery. MATERIAL AND METHODS: Our objective was to assess the efficacy of prophylactic amoxicillin with or without clavulanic acid in reducing the incidence of dry socket and/or infection after third molar extraction. We conducted a systematic review and meta-analysis consulting electronic databases and references in retrieved articles. We included double-blind placebo-controlled randomized clinical trials published up to June 2015 investigating the efficacy of amoxicillin with or without clavulanic acid on the incidence of the aforementioned conditions after third molar extraction. Relative risks (RRs) were estimated with a generic inverse-variance approach and a random effect model using Stata/IC 13 and Review Manager Version 5.2. Stratified analysis was performed by antibiotic type. RESULTS: We included 10 papers in the qualitative review and in the quantitative synthesis (1997 extractions: 1072 in experimental groups and 925 in controls, with 27 and 74 events of dry socket and/or infection, respectively). The overall RR was 0.350 (p< 0.001; 95% CI 0.214 to 0.574). We found no evidence of heterogeneity (I2 =0%, p = 0.470). The number needed to treat was 18 (95% CI 13 to 29). Five studies reported adverse reactions (RR=1.188, 95% CI 0.658 to 2.146, p =0.567). The RRs were 0.563 for amoxicillin (95% CI 0.295 to 1.08, p = 0.082) and 0.215 for amoxicillin/clavulanic acid (95% CI 0.117 to 0.395, p< 0.001). CONCLUSIONS: Prophylactic use of amoxicillin does not significantly reduce the risk of infection and/or dry socket after third molar extraction. With amoxicillin/clavulanic acid, the risk decreases significantly. Nevertheless, considering the number needed to treat, low prevalence of infection, potential adverse reactions to antibiotics and lack of serious complications in placebo groups, the routine prescription of amoxicillin with or without clavulanic acid is not justified
Asunto(s)
Humanos , Amoxicilina/farmacocinética , Combinación Amoxicilina-Clavulanato de Potasio/farmacocinética , Infección de la Herida Quirúrgica/prevención & control , Extracción Dental/métodos , Complicaciones Posoperatorias/prevención & control , Tercer Molar/cirugía , Resultado del TratamientoRESUMEN
OBJECTIVES: To describe the population pharmacokinetics of oral amoxicillin and to compare the PTA of current dosing regimens. METHODS: Two groups, each with 14 healthy male volunteers, received oral amoxicillin/clavulanic acid tablets on two separate days 1 week apart. One group received 875/125 mg twice daily and 500/125 mg three times daily and the other group 500/125 mg twice daily and 250/125 mg three times daily. A total of 1428 amoxicillin blood samples were collected before and after administration. We analysed the concentration-time profiles using a non-compartmental pharmacokinetic method (PKSolver) and a population pharmacokinetic method (NONMEM). The PTA was computed using Monte Carlo simulations for several dosing regimens. RESULTS: AUC0-24 and Cmax increased non-linearly with dose. The final model included the following components: Savic's transit compartment model, Michaelis-Menten absorption, two distribution compartments and first-order elimination. The mean central volume of distribution was 27.7 L and mean clearance was 21.3 L/h. We included variability for the central volume of distribution (34.4%), clearance (25.8%), transit compartment model parameters and Michaelis-Menten absorption parameters. For 40% fT>MIC and >97.5% PTA, the breakpoints were 0.125 mg/L (500 mg twice daily), 0.25 mg/L (250 mg three times daily and 875 mg twice daily), 0.5 mg/L (500 mg three times daily) and 1 mg/L (750, 875 or 1000 mg three times daily and 500 mg four times daily). CONCLUSIONS: The amoxicillin absorption rate appears to be saturable. The PTAs of high-dose as well as twice-daily regimens are less favourable than regimens with lower doses and higher frequency.
Asunto(s)
Combinación Amoxicilina-Clavulanato de Potasio/administración & dosificación , Combinación Amoxicilina-Clavulanato de Potasio/farmacocinética , Antibacterianos/administración & dosificación , Antibacterianos/farmacocinética , Absorción Fisiológica , Administración Oral , Adolescente , Adulto , Combinación Amoxicilina-Clavulanato de Potasio/sangre , Antibacterianos/sangre , Área Bajo la Curva , Relación Dosis-Respuesta a Droga , Voluntarios Sanos , Humanos , Masculino , Persona de Mediana Edad , Modelos Biológicos , Método de Montecarlo , Adulto JovenRESUMEN
We investigated the efficacies of cefotaxime (CTX) and amoxicillin (AMX)-clavulanate (CLA) (AMC) against extended-spectrum-ß-lactamase (ESBL)-producing Escherichia coli in vitro and in a murine model of urinary tract infection (UTI). MICs, the checkerboard dilution method, and time-kill curves were used to explore the in vitro synergism between cefotaxime and amoxicillin-clavulanate against two isogenic E. coli strains-CFT073-RR and its transconjugant, CFT073-RR Tc bla(CTX-M-15)-harboring a bla(CTX-M-15) plasmid and a bla(OXA-1) plasmid. For in vivo experiments, mice were separately infected with each strain and treated with cefotaxime, amoxicillin, and clavulanate, alone or in combination, or imipenem, using therapeutic regimens reproducing time of free-drug concentrations above the MIC (fT≥MIC) values close to that obtained in humans. MICs of amoxicillin, cefotaxime, and imipenem were 4/>1,024, 0.125/1,024, and 0.5/0.5 mg/liter, for CFT073-RR and CFT073-RR Tc bla(CTX-M-15), respectively. The addition of 2 mg/liter of clavulanate (CLA) restored the susceptibility of CFT073-RR Tc bla(CTX-M-15) to CTX (MICs of the CTX-CLA combination, 0.125 mg/liter). The checkerboard dilution method and time-kill curves confirmed an in vitro synergy between amoxicillin-clavulanate and cefotaxime against CFT073-RR Tc bla(CTX-M-15). In vivo, this antibiotic combination was similarly active against both strains and as effective as imipenem. In conclusion, the cefotaxime and amoxicillin-clavulanate combination appear to be an effective, easy, and already available alternative to carbapenems for the treatment of UTI due to CTX-M-producing E. coli strains.